Five years of COPD primary care: Patterns of management of high-risk COPD and opportunities for optimising care in Australia 2015-2019 (COPD Opportunity Analysis in Australia)

First published: 24/10/2022 Last updated: 21/02/2024





# Administrative details

| EU PAS number    |  |
|------------------|--|
| EUPAS49365       |  |
|                  |  |
| Study ID         |  |
| 19527            |  |
| DARWIN EU® study |  |
| DARWIN LOW Study |  |
| No.              |  |
| Study countries  |  |
| -                |  |
| Australia        |  |

#### Study description

The main aim for this "Opportunity Analysis" is to assess the management of patients with high-risk COPD over 5 years in Australian primary care and describe opportunities for treatment optimisation in line with the CONQUEST Quality Standards, over this period. The objectives per quality standards are: 1. Assess whether undiagnosed patients who potentially have high-risk COPD are actively and promptly identified in Australian primary care. 2. Assess whether high-risk patients with newly diagnosed COPD receive a proper assessment and quantification of future risk of exacerbations and cardiac events within 12 months of diagnosis. 3. Assess whether pharmaceutical and non-pharmacological therapy is provided to patients with high-risk COPD within 12 months of meeting criteria for high-risk COPD. 4. Assess whether high-risk patients diagnosed with COPD are followed up appropriately over a 12m period following baseline assessment

### **Study status**

Ongoing

## Research institutions and networks

### **Institutions**

| Optimum Patient Care Australia  |
|---------------------------------|
| Australia                       |
| First published: 01/02/2024     |
| <b>Last updated:</b> 01/02/2024 |
| Institution Not-for-profit      |

## Contact details

### **Study institution contact**

David Price dprice@opri.sg

Study contact

dprice@opri.sg

### **Primary lead investigator**

**David Price** 

**Primary lead investigator** 

## Study timelines

### Date when funding contract was signed

Actual: 29/06/2022

### Study start date

Actual: 01/08/2022

### **Date of final study report**

Planned: 31/12/2023

# Sources of funding

- Other
- Pharmaceutical company and other private sector

# More details on funding

# Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

# Study type

# Study type list

### Study type:

Non-interventional study

### Scope of the study:

Disease epidemiology

### Main study objective:

To describe real-world Australian primary care practice in COPD care over the period 2015-2019 in the light of the CONQUEST Quality Standards (QS), in patient populations with high-risk COPD which is either diagnosed or undiagnosed.

# Study Design

### Non-interventional study design

Cohort

# Study drug and medical condition

#### Medical condition to be studied

Chronic obstructive pulmonary disease

# Population studied

#### Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

### **Estimated number of subjects**

36000

# Study design details

#### **Outcomes**

Assessment of: active identification of undiagnosed patients with potential highrisk COPD, disease & quantification of future risk in newly diagnosed patients, appropriate pharmacological and non-pharmacological therapy provision in newly-diagnosed patients and already-diagnosed patients, whether high-risk COPD patients are followed up appropriately over a 12m period after index date.

### Data analysis plan

Descriptive analyses will be performed on the characteristics of high-risk patients and of primary care medical management of COPD in each patient group (undiagnosed, newly-diagnosed, already diagnosed). All summary statistics will be presented as percentages with counts (categorical variables) and mean/medians with standard deviation/interquartile ranges for normally and non-normally distributed continuous variables respectively. The yearly trends in Australian practice in COPD care will be described (2015-2019) in tables, and graphs to show the trends for key outcomes longitudinally over the 5-year assessment period.

## Data management

## **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

#### Data source(s)

Optimum Patient Care Research Database Australia (OPCRDA)

### **Data sources (types)**

# Use of a Common Data Model (CDM)

### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

### **Check completeness**

Unknown

### **Check stability**

Unknown

### **Check logical consistency**

Unknown

## Data characterisation

#### **Data characterisation conducted**

No